Cardiol Therapeutics is advancing clinical trials of its pure cannabidiol product, CardiolRx, for inflammatory heart disease treatment

2 min read | October 11, 2024 12:56 PM PDT | By Team Kalkine Media

Google News:

Cardiol Therapeutics is advancing clinical trials of its pure cannabidiol product, CardiolRx, for inflammatory heart disease treatment — Image source: Shutterstock

Recent News

Is Pitney Bowes Still Hiding Value After Its Rally?

What’s Driving Unity Bancorp Climb To New Highs?

Why United Parcel Service Is Back on The Market Radar?

Why Is Halliburton Facing Fresh Market Pressure?

Make Kalkine Media
My Trusted Source

Highlights

Cardiol Therapeutics Inc. is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with a lead candidate in clinical trials.
The company has successfully raised $15.5 million through a public offering to advance its clinical development efforts.
The FDA has granted Orphan Drug Designation for CardiolRx™, recognizing its potential to treat recurrent pericarditis.

Cardiol Therapeutics Inc. {NASDAQ:CRDL} is a clinical-stage life sciences company dedicated to the research and development of anti-inflammatory and anti-fibrotic therapies aimed at addressing heart disease. The company's primary drug candidate, CardiolRx™ (cannabidiol) oral solution, is currently in clinical development and is pharmaceutically manufactured for therapeutic use in cardiac conditions. Research indicates that cannabidiol can inhibit the activation of the inflammasome pathway, which plays a significant role in inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Recently, Cardiol Therapeutics announced that it successfully raised $15.5 million through a public offering. Canaccord Genuity has fully exercised its over-allotment option, acquiring an additional 1,265,625 Class A common shares at a specified price. This brings the total number of shares sold in this offering to 9,703,125, generating significant gross proceeds.

The company is advancing two key clinical studies: a Phase II multi-center open-label pilot study targeting recurrent pericarditis and the ARCHER trial, a Phase II multi-national randomized, double-blind, placebo-controlled study focused on acute myocarditis. The ARCHER trial recently achieved its enrollment goal of 100 patients, underscoring the commitment of the clinical collaborators and the dedication of participating patients.

Furthermore, in February 2024, Cardiol Therapeutics announced that the FDA granted Orphan Drug Designation for CardiolRx™ for the treatment of recurrent pericarditis. This designation is a significant validation of the drug’s potential to improve the lives of patients suffering from this debilitating condition and offers several benefits, including potential marketing exclusivity and expedited regulatory review opportunities. Overall, Cardiol Therapeutics continues to position itself as a leader in the development of innovative therapies for heart disease.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.